Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Post-hoc analysis could give new life to the Alzheimer’s drug aducanumab
Nature Medicine ( IF 58.7 ) Pub Date : 2020-11-02 , DOI: 10.1038/d41591-020-00031-z Carrie Arnold
Nature Medicine ( IF 58.7 ) Pub Date : 2020-11-02 , DOI: 10.1038/d41591-020-00031-z Carrie Arnold
The aducanumab saga continues as an FDA panel determines whether a post-hoc analysis could be enough to approve the drug
中文翻译：
事后分析可以为阿尔茨海默氏症药物阿杜卡单抗赋予新生命
随着 FDA 小组确定事后分析是否足以批准该药物，aducanumab 传奇仍在继续
更新日期：2020-11-02
中文翻译：
事后分析可以为阿尔茨海默氏症药物阿杜卡单抗赋予新生命
随着 FDA 小组确定事后分析是否足以批准该药物，aducanumab 传奇仍在继续
京公网安备 11010802027423号